Defective adenoviruses as novel vaccines for the Flaviviridae

Clinical and Diagnostic Virology

Volumn 10, Issue 2-3, 1998, Pages 187-194

  Stephenson, John ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Adenovirus; Flavivirus; Hepatitis; Hepatitis C virus (HCV); Tick borne encephalitis (TBE); Vaccine

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

ADENOVIRUS; CONFERENCE PAPER; DELETION MUTANT; FLAVIVIRUS; GENE THERAPY; GENE TRANSFER; HEPATITIS C VIRUS; HUMAN; JAPANESE ENCEPHALITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; TICK BORNE ENCEPHALITIS FLAVIVIRUS; VACCINATION; VIRUS INFECTION; YELLOW FEVER FLAVIVIRUS;

ADENOVIRIDAE; DEFECTIVE VIRUSES; FLAVIVIRIDAE; FLAVIVIRIDAE INFECTIONS; HEPACIVIRUS; HUMANS; VIRAL HEPATITIS VACCINES; VIRAL VACCINES;

ACARI; ADENOVIRIDAE; ANIMALIA; FLAVIVIRIDAE; FLAVIVIRUS; HEPATITIS C VIRUS; JAPANESE ENCEPHALITIS VIRUS; RNA VIRUSES; TICK-BORNE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS;

EID: 0032527364     PISSN: 09280197     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0197(98)00038-5     Document Type: Conference Paper

References (30)

1. Abbas A.K., Murphy K.M., Sher A. Functional diversity of helper T lymphocytes. Nature. 383:1996;787-793.
2. Abrignani S. Immune responses throughout hepatitis C virus (HCV) infection: HCV from the immune system point of view. Springer Semin Immunopathol. 19:1997;47-55.
3. Alter M.J. Epidemiology of hepatitis C. Hepatology. 26:1997;62S-65.
4. Blair GE, Proffitt JL, Blair-Zajdel ME. Modulation of MHC class I antigen expression in adenovirus infection and transformation. In: Blair GE, Pringle CR, Maudsley DJ, editors. Modulation of MHC Antigen Expression and Disease. Cambridge: Cambridge University Press, 1995: 192-232.
5. Charlton K.M., Artois M., Prevec L., Campbell J.B., Casey G.A., Wandeler A.I., Armstrong J. Oral rabies vaccination of skunks and foxes with a recombinant human adenovirus vaccine. Arch Virol. 123:1992;169-179.
6. Crooks A.J., Lee J.M., Easterbrook L.M., Timofeev A.V., Stephenson J.R. The NS1 protein of tick-borne encephalitis virus forms multimeric species upon secretion from the host cell. J Gen Virol. 75:1994;3453-3460.
7. Falgout B., Chanock R., Lai C.J. Proper processing of dengue virus nonstructural protein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a. J Virol. 63:1989;1852-1860.
8. Fooks AR. Structure of the measles virus nucleoprotein and its interaction with the immune system. Thesis, The Open University, Milton Keynes, 1995.
9. Fooks A.R., Schadeck E., Leibert U.G., Dowsett A.B., Rima B.K., Steward M.W., Stephenson J.R., Wilkinson G.W.G. High level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model. Virology. 210:1995;456-465.
10. Fooks AR, Jeevarajah D, Warnes A, Lee JM, Niewiesk S, ter Meulen V, Stephenson JR, Clegg JCS. In vivo expression of the measles virus hemagglutinin and fusion proteins using a replication-deficient adenovirus type vector: induction of protective immune responses by parenteral and oral immunisation in a murine model. J Gen Virol 1998; 79:1027-1031.
11. Freestone D.S., Ferris R.D., Weinberg A.L., Kelly A. Stabilised 17D strain yellow fever vaccine: dose response studies, clinical reactions and effect on hepatic function. J Biol Standard. 5:1977;181-186.
12. Heinz F.X., Kunz C., Fauma H. Preparations of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation. J Med Virol. 6:1980;213-221.
13. Huang C.H. Studies of Japanese encephalitis in China. Adv Virus Res. 27:1982;71-101.
14. Jacobs S.C., Wilkinson G.W.G., Stephenson J.R. High level expression of TBEV NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol. 66:1992;2086-2095.
15. Jacobs S.C., Stephenson J.R., Wilkinson G.W.G. Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Gen Virol. 75:1994;2399-2402.
16. Klockmann U., Bock H.L., Franke V., Hein B., Reiner G., Hilfenhaus J. Preclinical investigations of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine. J Biol Standard. 17:1989;331-342.
17. Lobigs M., Arthur C.E., Muellbacher A., Blanden R.V. The flavivirus non-structural protein NS3 is a dominant source of cytotoxic T-cell peptide determinants. Virology. 202:1994;195-201.
18. Popov O.V., Sumarakov A.A., Shkol'nik R.Y.a., El'bert L.B., Vorob'era M.A., Krutyanskaya G.L. Study of the reactogenicity and antigenic activity of a chromatographic cultural purified concentrated inactivated dry vaccine against tick-borne encephalitis. Zh Microbiol Epidemiol Immunobiol. 62:1985;34-39.
19. Prevec L., Schneider M., Rosenthal K.L., Belbeck L.W., Derbyshire J.B., Graham F.L. Use of human adenovirus-based vectors for antigen expression in animals. J Gen Virol. 70:1989;429-434.
20. Prevec L., Christie B.S., Laurie K.E., Bailey M.M., Graham F.L., Rosenthal K.L. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acq Immune Defic Syndr. 4:1991;568-576.
21. Rubin RA, Rourke LB. Adenovirus vaccines. In: Plotkin SA, Mortimer EA, editors. Vaccines, 2nd Ed. Saunders, Philadelphia: Saunders 1994: 475-501.
22. Stephenson J.R. Flavivirus vaccines. Vaccine. 6:1998;471-480.
23. Takaku K., Yamashita T., Osanai T., Yoshida I., Kato M., Goda H. Japanese encephalitis purified vaccine. Biken J. 11:1968;25-31.
24. Tauraso N.M., Coultrip R.L., Letgers R.L. Yellow fever vaccine IV. Reactogenicity and antibody response in volunteers inoculated with a vaccine free from contaminating avian leukosis viruses. Proc Soc Exp Biol Med. 139:1972;439-446.
25. Timofeev AV, Ozherelkov SV, Pronin AV, Deeva AV, Karganova GC, Elbert LB, Stephenson JR. Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus-based recombinant virus carrying the gene encoding the NS1 non-structural protein. J Gen Virol, 1998;79:689-695.
26. Warnes A, Fooks AR, Stephenson JR. Use of recombinant antigens as diagnostic reagents in enzyme-linked immunosorbant assays. In: Reischl U, editor, Modern Techniques in Clinical Diagnosis, Totawa, Humana Press, 1997 (in press).
27. Wilkinson G.W.G., Akrigg A. Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector. Nucl Acids Res. 20:1992;2233-2239.
28. Wilkinson G.W.G. Gene therapy and viral vaccination. Rev Med Microbiol. 5:1994;95-106.
29. Wilkinson G.W.G., Borysiewicz L.K. Gene therapy and viral vaccination: the interface. Br Med Bull. 51:1995;205-216.
30. Yang Y., Nunes F.A., Berencsi K., Furth E.E., Gonczol E., Wilson J.M. Cellular immunity to viral antigens limit E1-deleted adenoviruses for gene therapy. Proc Natl Acad Sci USA. 91:1994;4407-4411.